Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 8/20 | 0.76 |
| ▸ | SDC2 | P34741 | 8/20 | 0.76 |
| ▸ | VHL | P40337 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181199 | 1.00 | SDCBP (0.76) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL2179877 | 0.89 | SDCBP (0.62) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL2177896 | 0.86 | SDCBP (0.65) | SDCBPSDC2THRBALOX15MAPT | |
| SCHEMBL25424057 | 0.86 | SDCBP (0.68) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL29860045 | 0.86 | SDCBP (0.68) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL25424056 | 0.86 | SDCBP (0.68) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL23348860 | 0.84 | SDCBP (0.62) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL21616210 | 0.84 | SDCBP (0.62) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL30955020 | 0.84 | SDCBP (0.62) | SDCBPSDC2VHLLMNATHRB | |
| SCHEMBL18215253 | 0.83 | SDCBP (0.61) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317774-A | Pharmaceutical compositions comprising quinazoline compounds | 安斯泰来制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| US-20240182483-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2024-06-06 | — | — | US | disclosed |
| EP-4293024-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D-MUTATION KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023120742-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2023-06-29 | — | — | WO | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020009176-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | 田辺三菱製薬株式会社 | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | SDCBP 4283/4885SDC2 4882/4885VHL 635/4885 |
| US-20240182483-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | SDCBP 4456/4885SDC2 4877/4885VHL 49/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | SDCBP 4171/4885SDC2 4880/4885VHL 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.